EUVIMEDEUVIMED entdecken
Crossref

1673-P: ASC37 Oral Tablets, GLP-1R/GIPR/GCGR Triple Agonist Peptide, Achieved Average Absolute Oral Bioavailability of 4.2% in Nonhuman Primate Studies

JINZI J. WU, KUNHUA DONG

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1673-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von JINZI J. WU und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: ASC37 is an oral GLP-1R/GIPR/GCGR triple agonist peptide, discovered and developed in-house at Ascletis. Peptide Oral Transport ENhancement Technology (POTENT) is a proprietary technology of Ascletis for oral peptides. POTENT technology impedes enzymatic degradation of peptides and increases gastrointestinal permeability of peptides.

Methods

ASC37 oral tablets were developed utilizing Ascletis’ POTENT technology. The absolute oral bioavailability and drug exposure of ASC37 tablets were evaluated in non-human primate (NHP) models. ASC37 in vitro activity was also evaluated.

Results

ASC37, a GLP-1R, GIPR, and GCGR triple agonist peptide, was discovered and optimized in-house utilizing Ascletis’ Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD). ASC37 oral tablets achieved an average absolute oral bioavailability of 4.2%, approximately 9-, 30-, and 60-fold higher than semaglutide, tirzepatide, and retatrutide in the oral SNAC formulation, respectively, in head-to-head non-human primate (NHP) studies. ASC37 oral tablets’ drug exposure, as measured by the area under curve (AUC), was approximately 57-fold of retatrutide’s drug exposure in head-to-head NHP studies. Average observed half-life (as measured by time to 50% Cmax) of ASC37 oral tablets was approximately 56 hours in NHP studies, supporting once daily and less frequent oral dosing. ASC37 in vitro activity was approximately 5-, 4- and 4-fold more potent than retatrutide for GLP-1R, GIPR and GCGR, respectively.

Conclusion

ASC37 is a promising oral GLP-1R/GIPR/GCGR triple agonist peptide for clinical development Disclosure J.J. Wu: None. K. Dong: None.

Zitieren

APA

WU, J. J., & DONG, K. (2026). 1673-P: ASC37 Oral Tablets, GLP-1R/GIPR/GCGR Triple Agonist Peptide, Achieved Average Absolute Oral Bioavailability of 4.2% in Nonhuman Primate Studies. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1673-p

Vancouver

WU JJ, DONG K. 1673-P: ASC37 Oral Tablets, GLP-1R/GIPR/GCGR Triple Agonist Peptide, Achieved Average Absolute Oral Bioavailability of 4.2% in Nonhuman Primate Studies. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1673-p

BibTeX
@article{WU2026,
  author = {WU, JINZI J. and DONG, KUNHUA},
  title = {1673-P: ASC37 Oral Tablets, GLP-1R/GIPR/GCGR Triple Agonist Peptide, Achieved Average Absolute Oral Bioavailability of 4.2% in Nonhuman Primate Studies},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1673-p}
}
Kostenlos starten →